Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion.
Forkhead box protein 3-positive regulatory T (Treg) cells are indispensable for the maintenance of self-tolerance and immune homeostasis. They can also be exploited for the treatment of immunologic diseases, including autoimmune diseases and allergy, by way of activating and expanding antigen-specific Treg cells in vivo. Cell therapy with in vitro activated and expanded Treg cells can be another therapeutic modality. The feasibility of such Treg cell-based therapeutic strategies is discussed based on recent advances in our understanding of the molecular and cellular basis of Treg cell development and function.
Department of Experimental Pathology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan.
Makoto
M
Miyara
Kajsa
K
Wing
Shimon
S
Sakaguchi
D000818:Animals; D015551:Autoimmunity; D016207:Cytokines / Q000502:physiology; D051858:Forkhead Transcription Factors / Q000032:analysis*; D006801:Humans; D006967:Hypersensitivity / Q000276:immunology / Q000628:therapy*; D007108:Immune Tolerance; D007167:Immunotherapy; D008213:Lymphocyte Activation; D016853:Muromonab-CD3 / Q000494:pharmacology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology* / Q000502:physiology
D016207:Cytokines; C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors; D016853:Muromonab-CD3